Skye Bioscience, Inc.

EMBI

US83086J2006

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:00:00 16/07/2024 BST			5-day change	1st Jan Change
6.64 ^USD	+5.40%		+19.00%	+144.12%

07-11	Skye Bioscience Establishes Metabolic Clinical and Scientific Advisory Board to Support Development of Nimacimab	CI
07-03	Skye Bioscience, Inc. Announces Board and Committee Changes, Effective August 1, 2024	CI

Emerald Bioscience Inc. Announces Resignation of Brian Murphy, as A Director

August 10, 2020 at 01:30 pm

Emerald Bioscience Inc. announced that the board of directors has concurrently accepted the resignation of Brian Murphy, MD, as a director of the company.

Latest news about Skye Bioscience, Inc.

Skye Bioscience Establishes Metabolic Clinical and Scientific Advisory Board to Support Development of Nimacimab	07-11	CI
Skye Bioscience, Inc. Announces Board and Committee Changes, Effective August 1, 2024	07-03	CI
Skye Bioscience, Inc.(NasdaqGM:SKYE) added to Russell Small Cap Comp Value Index	06-30	CI
Skye Bioscience, Inc.(NasdaqGM:SKYE) added to Russell Small Cap Completeness Index	06-30	CI
Skye Bioscience, Inc.(NasdaqGM:SKYE) added to Russell 3000 Value Index	06-30	CI
Skye Bioscience, Inc.(NasdaqGM:SKYE) added to Russell 2000 Index	06-30	CI
Skye Bioscience, Inc.(NasdaqGM:SKYE) added to Russell 3000E Index	06-30	CI
Skye Bioscience, Inc.(NasdaqGM:SKYE) added to Russell 3000 Growth Index	06-30	CI
Skye Bioscience, Inc.(NasdaqGM:SKYE) added to Russell Microcap Index	06-30	CI
Skye Bioscience, Inc.(NasdaqGM:SKYE) added to Russell 2500 Value Index	06-30	CI
Skye Bioscience, Inc.(NasdaqGM:SKYE) added to Russell Microcap Growth Index	06-30	CI
Skye Bioscience, Inc.(NasdaqGM:SKYE) added to Russell 2000 Value Index	06-30	CI
Skye Bioscience, Inc.(NasdaqGM:SKYE) added to Russell 3000E Growth Index	06-30	CI
Skye Bioscience, Inc.(NasdaqGM:SKYE) added to Russell 2000 Growth Index	06-30	CI
Skye Bioscience, Inc.(NasdaqGM:SKYE) added to Russell 2000 Dynamic Index	06-30	CI
Skye Bioscience, Inc.(NasdaqGM:SKYE) added to Russell Microcap Value Index	06-30	CI
Skye Bioscience, Inc.(NasdaqGM:SKYE) added to Russell 2500 Growth Index	06-30	CI
Skye Bioscience, Inc.(NasdaqGM:SKYE) added to Russell Small Cap Comp Growth Index	06-30	CI
Skye Bioscience, Inc.(NasdaqGM:SKYE) added to Russell 2500 Index	06-30	CI
Skye Bioscience, Inc.(NasdaqGM:SKYE) added to Russell 3000 Index	06-30	CI
Skye Bioscience, Inc.(NasdaqGM:SKYE) added to Russell 3000E Value Index	06-30	CI
Skye Bioscience, Inc.(NasdaqGM:SKYE) added to S&P TMI Index	06-23	CI
Skye Bioscience, Inc. Concentrates Strategy and Clinical Development Focus on Nimacimab Metabolic Program	06-10	CI
Skye Bioscience to stop eye disease drug development after failing mid-stage study	06-10	RE
Skye Bioscience to discontinue development of eye disease treatment	06-10	RE

Skye Bioscience, Inc. is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel classes of therapeutic drugs that modulate the endocannabinoid system. The Company's clinical assets focus on the modulation of cannabinoid receptor 1 (CB1) to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis and neurodegeneration, such as obesity and glaucoma. Its Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion (SBI-100 OE), a CB1 agonist (activator), being developed for the treatment of glaucoma and ocular hypertension. The Company's Phase 2 study in obesity is designed to evaluate nimacimab's weight loss potential either as a single agent or in combination with a glucagon-like peptide-1 (GLP-1) agonist like semaglutide.

Sector

Biotechnology & Medical Research

Calendar

24/07/2024 - Investor Meeting - Key Opinion Leader

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

6.64 USD

Average target price

18.25 USD

Spread / Average Target

+174.85%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
SKYE BIOSCIENCE, INC.	+144.12%	177M
MODERNA, INC.	+25.83%	46.56B
LONZA GROUP AG	+45.38%	41.67B
IQVIA HOLDINGS INC.	+0.69%	41.16B
ALNYLAM PHARMACEUTICALS, INC.	+30.52%	32.4B
ICON PUBLIC LIMITED COMPANY	+22.30%	28.18B
CELLTRION, INC.	-6.35%	28.1B
UNITED THERAPEUTICS CORPORATION	+49.25%	14.52B
MEDPACE HOLDINGS, INC.	+49.18%	13.74B
BIO-TECHNE CORPORATION	+3.45%	12.17B

Other Biotechnology & Medical Research

Skye Bioscience, Inc.

Equities

EMBI

US83086J2006

Biotechnology & Medical Research

Emerald Bioscience Inc. Announces Resignation of Brian Murphy, as A Director

Latest news about Skye Bioscience, Inc.

Chart Skye Bioscience, Inc.

Company Profile

Income Statement Evolution

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Biotechnology & Medical Research